Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...

The infusion rate should be reduced by 50% in case of nonserious infusion reactions In patients who develop serious infusion reactions, cetuximab should be discontinued immediately and permanently ...

The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.

Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Penile Cancer. According to GlobalData, Phase I drugs for Penile Cancer does ...

Cetuximab is an epidermal growth factor (EGFR) inhibitor that is used to treat metastatic colorectal cancer. However, cetuximab produces an acne-like rash in over 80% of patients treated. Although ...